Phaseline

Companies › EuBiologics

EuBiologics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EuHZV
Herpes zoster (shingles) vaccine
–Phase 1Varicella Zoster Virus Infection–
EuRSV
RSV-1 and RSV-2 vaccine
–Phase 1Respiratory Syncytial Virus Infections–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06409494EuHZVPhase 1Varicella Zoster Virus InfectionInfectious diseaseJul 2025
NCT06216093EuRSVPhase 1Respiratory Syncytial Virus InfectionsInfectious diseaseJul 2025

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.